1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Glenmark Life Sciences Limited

Glenmark Life Sciences Limited

GLS.BO
Glenmark Life Sciences LimitedIN flagBombay Stock Exchange
1,085.80
INR
- -
- -
133.05BMarket Cap
Glenmark Life Sciences Limited
GLS.BO
(Bombay Stock Exchange)

Recent

price

1,085.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
TTM
FRC
111.06
121.96
151.92
177.62
167.13
178.31
177.58
Revenue per Share
23.89
25.55
28.69
35.63
38.11
38.43
36.05
Basic EPS, GAAP
0.08
11.74
26.13
39.6
11.69
23.22
- -
Free Cash Flow per Basic Share
- -
- -
- -
10.95
31.5
22.5
- -
Dividend per Share
0.16
0.16
61.44
88.99
91.94
107.43
- -
Book Value per Share
6.67
32.2
60.79
173.91
173.04
189.14
- -
Tangible Book Value per Share
123
123
123
118
123
123
123
Basic Weighted Avg Shares
13,608
14,943
18,614
20,874
20,478
21,848
21,755
Sales/Revenue/Turnover
30.08
29.7
30.18
27.73
29.34
28.48
26.1
Operating Margin (%)
193
294
334
379
421
535
592
Depreciation Expense
2,927
3,131
3,516
4,187
4,670
4,709
4,417
Net Income, GAAP
27.53
25.64
25.35
25.88
25.72
25.41
25.45
Effective Tax Rate (%)
21.51
20.95
18.89
20.06
22.8
21.55
20.3
Profit Margin (%)
-4,497
-1,474
1,776
13,806
13,538
14,772
- -
Working Capital
- -
- -
- -
12
171
148
- -
LT Debt
881
4,017
7,527
20,543
21,382
23,323
- -
Total Equity
- -
131.86
71.29
30.26
21.05
20.53
- -
Return on Invested Capital (%)
- -
17,063.06
110.49
48.79
42.59
38.08
1,055.38
Return on Capital (%)
- -
15,974.39
93.17
46.56
42.99
38.55
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
- -
26
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
134
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
123
- -
Market Capitalization
106,539
129,673
120,384

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
- -
20,961
- -
Cash, Cash Equivalents & STI
- -
5,302
- -
Accounts Receivable, Net
- -
7,751
- -
Inventories
- -
6,892
- -
Total Current Liabilities
- -
4,637
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
26
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
125.86%
9.08%
Free Cash Flow
- -
2,820.67%
98.69%
Net Income, GAAP
- -
10.15%
0.84%
Sales/Revenue/Turnover
- -
10.26%
6.69%
Total Cash Common Dividend
- -
- -
-28.56%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
4,899
5,093
5,407
5,079
20,478
2024
5,784
5,954
5,728
4,382
21,848
2025
5,886
5,069
6,418
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
8.87
8.72
8.57
- -
38.11
2024
11.05
9.69
9.69
- -
38.43
2025
9.1
7.78
11.18
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
31.5
2024
- -
- -
- -
- -
22.5
2025
- -
- -
- -
- -
- -
Similar Companies
Gujarat Themis Biosyn Ltd. (GUJTHEM.NS)
Unichem Laboratories Limited (UNICHEMLAB.BO)
Link Reservations Inc. (LRSV)
Aurobindo Pharma Limited (AUROPHARMA.NS)
Mallinckrodt plc (MNKPF)
Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ)
Business
Alivus Life Sciences Limited Glenmark Life Sciences Limited, formerly Glenmark Life Sciences Limited and a subsidiary of Nirma Limited, develops and manufactures high-value, non-commoditized active pharmaceutical ingredients (APIs) and provides contract development and manufacturing organization (CDMO) services for chronic therapeutic areas including cardiovascular disease, central nervous system disorders, pain management, diabetes, oncology, and anti-infectives. The company offers a diversified portfolio of over 160 APIs such as Amiodarone and Telmisartan for cardiovascular treatments; Teneligliptin and Linagliptin for diabetes management; Clindamycin and Lopinavir for anti-infectives; and specialized oncology molecules, alongside end-to-end CDMO support encompassing custom synthesis, process development, scale-up from research to commercial production, and cGMP-compliant manufacturing inspected by regulators like the US FDA, PMDA Japan, and EDQM Europe. Alivus Life Sciences Limited supplies these products to more than 700 customers, including the world's top 20 generic pharmaceutical companies, across global markets in North America, Europe, Japan, Latin America, India, and the rest of the world (ROW); it operates four manufacturing facilities in India, including sites at Mohol Solapur (registered office), Kurkumbh Pune, Ankleshwar, and Mahape Navi Mumbai R&D, plus corporate offices in Mumbai's Andheri East. Founded in 2011 as part of Glenmark Pharmaceuticals' API business unit that originated in 2001, the company is headquartered at Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur, Maharashtra, India, with its corporate office at 4th Floor, OIA House, 470 Cardinal Gracious Road, Andheri East, Mumbai. In recent developments, Nirma Limited acquired a 75% majority stake from Glenmark Pharmaceuticals in March 2024 for approximately Rs 5,651 crore, establishing Nirma as the new promoter and enabling Glenmark's strategic shift toward innovative branded formulations; the company rebranded to Alivus Life Sciences in early 2025 to reflect its evolving vision for growth in APIs and CDMO, strengthening global presence amid a temporary Ankleshwar facility closure that impacted first-half FY25 revenues but supported improved gross margins over 55% and a projected high single-digit growth for the full year.